about
De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human LiverDerivation and analysis of viscoelastic properties in human liver: impact of frequency on fibrosis and steatosis staging.Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver diseaseRelationship between methylome and transcriptome in patients with nonalcoholic fatty liver diseaseGender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.Reply to Kim et al.NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment OptionsSimtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisLongitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of SelonsertibBranched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot studyVibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver DiseaseNonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosisNonalcoholic Fatty Liver DiseaseHistologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase LevelsRosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitisAssociation Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic SteatohepatitisPegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trialPosttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity ParadoxPAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver diseaseFactors Associated With Histologic Response in Adult Patients With Nonalcoholic SteatohepatitisRelationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitisLiver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical ChallengesRandomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionCenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
P50
Q30235007-A8B6A174-077E-444A-B861-060CD9C9F1F7Q30277347-B1FC68FE-21F2-43E8-AEBF-4930185385DCQ30380564-DAE39ABE-AEBB-4522-BC26-E0B1D0FAC89CQ30413810-FAE45E15-1766-4210-B2B5-11A2557A821EQ34560114-CD959166-4B4D-4868-B71A-DE4ECDDC4EDCQ34636500-B869B663-376C-47CB-A9F8-6194C744D2CAQ37029735-5EE766BA-A3B3-4F9E-BC40-471EE4338EF5Q37248725-06358AA2-16B6-45B5-B484-1C5002B51214Q37665974-1BFA6CD6-52F4-4FFA-9EF5-F9A3A4B8E816Q37673981-F5665217-C41F-4B3C-B6EC-13275F7D1E12Q37696171-A6CD306A-FE3A-477A-9D62-D83950B08D71Q38959081-6A965250-1E2F-46C2-8BFE-497F994DF3EDQ40082820-F0F049D3-50E5-4BF2-913A-FCFAC55FD50EQ43225152-8B3B248F-EE93-4A3B-8B43-6047D4513D99Q45066338-9F10119A-1F61-4167-993C-DAB4C9E97BDFQ45070782-5B1BB0A6-0387-4C6B-8701-AC28ABB7050DQ46057830-7B4E55F0-EC8B-4F92-8047-0D2B2220454BQ46566732-20190B16-BE85-4CEC-8D1A-7A20BAA27E4BQ50147806-EF3D8B31-BDB5-4B4F-A7A8-144A82A69D3FQ50890464-599F8FBC-B38F-4613-B2BD-42CF65E6B951Q51071827-4C0072D8-8345-4261-8FDA-083FA22D0CFAQ51742682-138653F8-A2D7-4340-937E-0D5BAE7E0836Q56333996-FA860EF6-69D2-42E8-985B-7833758F0EA5Q56342176-2A427337-EDF1-40A9-986A-28FAFED71E15Q57038206-8CA06DF5-4629-40C5-81CF-9F5C984B0694Q59126498-693AC9FB-A38A-4E84-AEC2-74F51922C415Q70886743-E99BE759-B567-45A7-8C56-A6F012E13466Q88041232-52518084-5C7D-4E2E-B548-7FFE7B69EF4BQ89387982-DEA62AD9-B66A-4437-B229-E6402AB1D70BQ90091780-EDA09B9A-894E-44C5-ADAF-7BF8B8FC1AD0Q90358871-57008D2B-9942-4DB1-876E-AF23F559103EQ90384598-30561CFC-01E8-4850-A1BD-8DC627AECB1CQ90566894-4C100932-CB6D-4B3F-81B0-5381630462B3Q91007276-EF5BC423-5A33-4C91-AEDC-54B53AC33719Q91022449-0F2576F1-7AF5-4EDC-B85D-276120437F99Q91484128-E318C19D-F36B-4374-9D7E-824845D2037AQ91726928-285089B7-3E7A-4410-9BE2-ED11EDADA857Q91945515-22A4483B-3BB0-4D70-8B9F-70EE6F503F18Q92216015-0C15A44B-1C5D-4DE6-A874-9852FF057DBCQ92280456-68251C8A-0442-46E4-8BD1-2AEB0C138BDA
P50
description
researcher ORCID ID = 0000-0002-5001-8618
@en
name
Manal F Abdelmalek
@ast
Manal F Abdelmalek
@en
Manal F Abdelmalek
@nl
type
label
Manal F Abdelmalek
@ast
Manal F Abdelmalek
@en
Manal F Abdelmalek
@nl
prefLabel
Manal F Abdelmalek
@ast
Manal F Abdelmalek
@en
Manal F Abdelmalek
@nl
P108
P31
P496
0000-0002-5001-8618